You are here: Home: BCU 3 | 2006: Editor's Note: Select publications

SELECT PUBLICATIONS

Al-Hajj A, O’Regan R. Selection of optimal adjuvant endocrine therapy for early-stage breast cancer. Curr Treat Options Oncol 2006;7(2):153-65. Abstract

Cheung KL et al. Selection of primary breast cancer patients for adjuvant endocrine therapy — Is oestrogen receptor alone adequate? Breast Cancer Res Treat 2001;65(2):155-62. Abstract

Chowdhury S, Ellis P. Extended adjuvant endocrine therapy of early breast cancer.Curr Med Res Opin 2005;21(12):1985-95. Abstract

Gee JM et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005;12(Suppl 1):99-111. Abstract

Goldhirsch A et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16(10):1569-83. Abstract

Henderson IC, Piccart-Gebhart MJ. The evolving role of aromatase inhibitors in adjuvant breast cancer therapy. Clin Breast Cancer 2005;6(3):206-15. Abstract

Ingle JN. Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clin Cancer Res 2006;12(3 Pt 2):1031-6. Abstract

Kaufmann M, Rody A. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: Why, who and how long? Eur J Obstet Gynecol Reprod Biol 2006;126(2):146-54.[Epub ahead of print]. Abstract

Koberle D, ThŸrlimann B. Adjuvant endocrine therapy in postmenopausal breast cancer patients. Breast 2005;14(6):446-51. Abstract

Kumar S, Leonard RC. Adjuvant hormonal therapy in early breast cancer. Oncology (Williston Park) 2005;19(11):1425-8. Abstract

Wardley AM. Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. Clin Breast Cancer 2006;6(Suppl 2):45-50. Abstract

Search our Site: